Literature DB >> 32894020

Discovery and Optimization of Small-Molecule Ligands for V-Domain Ig Suppressor of T-Cell Activation (VISTA).

Moustafa T Gabr1,2, Sanjiv S Gambhir1,2,3.   

Abstract

V-domain Ig suppressor of T-cell activation (VISTA) is an immune checkpoint that affects the ability of T-cells to attack tumors. A FRET-based high throughput screening identified NSC622608 as the first small-molecule ligand for VISTA. Investigation of the interaction of NSC622608 with VISTA using STD NMR and molecular modeling enabled the identification of a potential binding site in VISTA for NSC622608. Screening NSC622608 against a library of single-point VISTA mutants revealed the key residues in VISTA interacting with NSC622608. Further structural optimization resulted in a lead with submicromolar VISTA binding affinity. The lead compound blocked VISTA signaling in vitro, enhanced T-cell proliferation, and restored T-cell activation in the presence of VISTA-expressing cancer cell lines. This work would enable future development of small molecules targeting VISTA as immunomodulators and imaging probes.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32894020     DOI: 10.1021/jacs.0c07276

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  4 in total

Review 1.  IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy.

Authors:  Xi-Yang Tang; Yan-Lu Xiong; Xian-Gui Shi; Ya-Bo Zhao; An-Ping Shi; Kai-Fu Zheng; Yu-Jian Liu; Tao Jiang; Nan Ma; Jin-Bo Zhao
Journal:  Biomark Res       Date:  2022-07-13

Review 2.  VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses.

Authors:  Chenyang Wu; Xin Cao; Xiaojin Zhang
Journal:  RSC Med Chem       Date:  2021-07-06

Review 3.  VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.

Authors:  Long Yuan; Jahnavi Tatineni; Kathleen M Mahoney; Gordon J Freeman
Journal:  Trends Immunol       Date:  2021-01-23       Impact factor: 16.687

4.  M351-0056 is a novel low MW compound modulating the actions of the immune-checkpoint protein VISTA.

Authors:  Xinlei Hu; Chenxin Qie; Jingwei Jiang; Xiaoxue Xie; Wenting Chen; Wanmei Liu; Jun Liu
Journal:  Br J Pharmacol       Date:  2021-02-20       Impact factor: 9.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.